



MEDICATION POLICY

Generic Name: Denosumab

Therapeutic Class or Brand Name: Prolia®

Applicable Drugs (if Therapeutic Class): N/A

Date of Origin: 1/15/16

Date Last Reviewed/Revised: 6/16/16

GPI Code: 30044530002020

Prior Authorization Criteria (may be considered medically necessary when criteria I through V are met):

- I. Documented diagnosis of one of the following conditions A through D AND must meet criteria listed under applicable diagnosis:
 - A. Treatment of postmenopausal women with osteoporosis AND criterion 1 is met:
 1. Documented baseline bone mineral density (BMD) T-score at of -2.5 or less.
 - B. Treatment to increase bone mass in men with osteoporosis AND criterion 1 is met:
 1. Documented baseline bone mineral density (BMD) T-score at of -2.5 or less.
 - C. Treatment to increase bone mass in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
 - D. Treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
- II. Documented trial and failure of (i.e. progression of bone loss as recorded by bone mineral density measurements or occurrence of an osteoporotic fracture after a minimum of a 12 month trial), intolerance to, or contraindication to bisphosphonate therapy.
- III. Documentation that patient is at high risk for fracture (i.e. history of osteoporotic fracture, multiple risk factors for fracture, etc.).
- IV. Documentation that patient will also take calcium 1000 mg daily and at least 400 IU vitamin D daily.
- V. Minimum age requirement: 18 years old.

Exclusion Criteria:

- Hypocalcemia.
- Pregnancy.
- Coadministration of Prolia® with Xgeva®.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

Other Criteria:

- N/A

Quantity/Days Supply Restrictions:

- One 60 mg injection every 6 months.

Approval Length:

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

Appendix:

N/A

References:

1. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf.
2. <http://nof.org/files/nof/public/content/file/2791/upload/919.pdf>.
3. Medi-Span.
4. http://www.summacare.com/libraries/documents/prolia_pa_criteria_medicare_only.sflb.ashx.
5. <http://blue.regence.com/trgmedpol/drugs/dru223.pdf>.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

<i>Historical Tracking Of Changes Made To Policy</i>	
<i>6/16/2016</i>	1. Changed “II. Documentation that patient is at high risk...III. Documented trial and failure of...” to “II. Documented trial and failure of...III. Documentation that patient is at high risk...” under Prior Authorization Criteria.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.